











Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or Version of Record. 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/150071                                                                            
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  
 
Copyright © and all moral rights to the version of the paper presented here belong to the 
individual author(s) and/or other copyright owners. To the extent reasonable and 
practicable the material made available in WRAP has been checked for eligibility before 
being made available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 






Measuring health-related quality of life in chronic headache: a comparative evaluation of the 
Chronic Headache Quality of Life Questionnaire and Headache Impact Test (HIT-6)  
Kirstie L Haywood*1, Felix Achana*2,3, Vivien Nichols,2, Gemma Pearce4, Barbara Box2, Lynne 
Muldoon2, Shilpa Patel2, Frances Griffiths5, Kimberly Stewart2, Martin Underwood2,6, Manjit M 
Matharu7 ON BEHALF OF THE CHESS TEAM. 
1. Warwick Research in Nursing, Warwick Medical School, University of Warwick, 
Coventry, UK 
2. Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, 
UK 
3. Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK 
4. School of Psychology, Social and Behavioural Sciences. Coventry University. Coventry, 
UK. 
5. Social Science and Systems in Health, Warwick Medical School, University of Warwick, 
Coventry, UK 
6. University Hospitals Coventry and Warwickshire, Coventry, UK 
7. The Headache Group, National Hospital for Neurology and Neurosurgery, University 
College of London Hospitals NHS Foundation Trust 
 






Warwick Research in Nursing, Warwick Medical School, University of Warwick. CV4 7AL. 







Objective: To compare the quality and acceptability of a new headache-specific patient-
reported measure the Chronic Headache Quality of Life Questionnaire (CHQLQ), with the 
Headache Impact Test–6 item (HIT-6), in people meeting an epidemiological definition of 
chronic headaches. 
Methods: Participants in the feasibility stage of the Chronic Headache Education and Self-
management Study (CHESS) (N=130) completed measures three times during a 12-week 
prospective cohort study. Data quality, measurement acceptability, reliability, validity, 
responsiveness to change, and score interpretation were determined. Semi-structured 
cognitive interviews explored measurement relevance, acceptability, clarity, and 
comprehensiveness. 
Results: Both measures were well completed with few missing items. The CHQLQ’s inclusion of 
emotional wellbeing items increased its relevance to participant’s experience of chronic 
headache. End effects were present at item level only for both measures. Structural assessment 
supported the three and one-factor solutions of the CHQLQ and HIT-6, respectively. Both the 
CHQLQ (range 0.87 to 0.94) and HIT-6 (0.90) were internally consistent, with acceptable 
temporal stability over 2-weeks (CHQLQ range 0.74 to 0.80; HIT-6 0.86). Both measures 
responded to change in headache-specific health at 12-weeks (CHQLQ smallest detectable 





Conclusions: While both measures are structurally valid, internally consistent, temporally stable 
and responsive to change, the CHQLQ has greater relevance to the patient experience of 
chronic headache.  
 










Chronic headaches, that can be defined epidemiologically as headaches on 15 or more days per 
month for at least three months,1-3 have profound effects on people’s lives. Those affected 
describe strained relationships, and that the spectre of headaches can be a crucial driver of 
their behaviour.4 When testing treatments for these chronic headache disorders, an 
international, multi-stakeholder consensus process rated the measurement of the overall 
health impact of chronic headaches as being at least as important as counting headaches days.5 
These health impacts should be assessed using Patient-Reported Outcome Measures (PROMs) 
with robust evidence of measurement quality, relevance, and acceptability.5, 6 There is 
substantial heterogeneity in PROMS used in trials of headache disorders.7 
 
A 2018 systematic review of PROMS for headaches found the strongest, albeit limited, evidence 
was for two headache-specific measures 7 the Migraine-Specific Questionnaire (MSQ v2.1)8 and 
the six-item Headache Impact Test (HIT-6).9 However, essential evidence of data quality and 
interpretation, reliability, and responsiveness was mostly absent or of insufficient quality. 
Moreover, the relevance and acceptability of these measures to people with headache were 
not explored. The use of PROMs that lack relevance to patients, and hence fail to capture the 







We report here on a mixed-methods comparative evaluation of the measurement and practical 
properties of the HIT-6 and an adaption of the MSQ v2.1 to make it suitable for people with 








The Chronic Headache Education and Self-Management Study (CHESS) is a programme grant 
funded by the UK’s National Institute for Health Research (RP-PG-1212-20018) to test the 
effectiveness of a supportive self-management intervention for people living with chronic 
headache disorders.11 This current work forms part of the feasibility study, reported elsewhere, 
(January 2016-April 2017)(Black Country Research Ethics Committee (15/WM/0165)).12 In 
summary, participants completed questionnaires on three occasions during a 12-week 
prospective cohort study (baseline, two and 12-weeks). 
 
Study population 
We recruited people living with chronic headaches, predominately chronic migraine or chronic 
tension-type headache from general practices in the West Midlands region of the UK. Practices 
wrote to people who had, in the previous two years, consulted for headaches or had a 
prescription for a migraine specific drug (i.e. triptans/pizotifen) inviting expression of interest in 
the study.  In a subsequent telephone interview, study team members assessed if participants 
met an epidemiological definition of chronic headaches; headache for 15 or more days per 
month for at least 3 months.1-3 For this validation of a generic headache-related quality of life 
outcome that is not diagnosis specific, this the appropriate population. However, as part of this 
overall programme of work we also validated a classification interview in this population. Of the 
131 people included in this report 107 (82%) also had paired telephone interviews with 
research nurses and doctors from the National Migraine Centre.  The final classification was: 





headache 6 (6%), cluster headache 2 (2%), hemicrania continua 1 (1%). Over half, 44/74 (59%), 
also had medication overuse defined as ‘headache occurring on 15 or more days per month 
taking acute or symptomatic headache medication (on 10/15 or more days per month, 
depending on the medication) for more than 3 months’. The sample size was driven by 
requirements for validation of a chronic headache classification interview. This work is 
described in detail elsewhere.13 
 
Patient-reported outcome measures  
The feasibility study included general headache-specific (not diagnosis specific), generic and 
domain-specific measures and a headache-specific health transition question (detailed in 
Appendix 1). The CHQLQ is a 14-item questionnaire, which assesses the functional aspects of 
headache-related quality of life, producing three domain scores (role-prevention, role-
restriction, and emotional function).8 Modification of the CHQLQ from the MSQ (v2.1) simply 
involved replacing he word ‘migraines’ with ‘headaches’ throughout the questionnaire. The HIT-
6 is a 6-item questionnaire, which produces a single index score of headache impact on 




Psychometric properties of the measures were compared14, 15 (Appendix 2).  





Item-scale characteristics, completion rates (missing data) and percentage of computable scale 
scores are reported.15, 16 Interpretability was informed by evidence of end effects and 
calculation of the minimal important change (MIC) – the smallest change in score perceived as 
important by participants )15 -, calculated as the mean change score for people reporting 
'minimal change' in their headache at 12-weeks. 
 
Structural validity and internal consistency 
An exploratory factor analysis on baseline data hypothesised that the CHQLQ’s original three-
factor solution would be retained. Absolute item loadings ≥0.45 were accepted as sufficient 
correlation with a principal component to support domain inclusion. Confirmatory Factor 
Analysis was then used to confirm the three- and one-factor structures of the CHQLQ and HIT-6, 
respectively. Factor loadings exceeding 0.3-0.4 were judged to be meaningful.15-17 Internal 
consistency was assessed with Cronbach's alpha;15, 16 values between 0.7 and 0.90 suggest a 
good to excellent agreement between items and the total (domain) score.15, 16  
 
Reliability and measurement error 
Two-week test-retest reliability (intra-class correlation coefficient (ICC 2,1)) was assessed in 
those indicating no change in their headache. We calculated the standard error of measurement 
(SEM) to determine the extent of absolute measurement error.6, 18, 19 The SEM supports score 
interpretation by accounting for variability, or error, in measurement - only a change greater 
than measurement error is considered ‘real’.18 The SEM was subsequently converted into the 





measurement error; the SDC was calculated for individuals and for groups.19, 20 The SDC allows 
one to rule out measurement error (i.e. distinguishing measurement error from true change) 
when assessing the reliability of a self-reported measure to detect change in health status. 
Thus, a score change greater than the SDC value is necessary to provide evidence of true 
change (improvement or deterioration) in health-status.  
 
Construct validity 
Score correlation between measures was assessed to evaluate convergent validity (Pearson's 




Responsiveness reflects the ability of a measure to detect real change in health that is greater 
than measurement error.  
i. Smallest Detectable Change (SDC) 
We calculated the absolute measurement error at 12-weeks (standard error of measurement 
(SEM) and the smallest detectable change (SDC)), to represent the smallest change in score that 
is greater than measurement error in patients reporting change in headache at 12-weeks. We 
calculated the minimal important change (MIC) as the mean change in those reporting minimal 
improvement or deterioration at 12-weeks. We calculated the minimal important clinical 
difference (MICD) as the mean change in score in those who are 'somewhat better' minus the 





ii. Criterion-based assessment  
Receiver operating characteristic (ROC) curves were calculated to assess the ability of measures 
to discriminate between people whose headache had improved or deteriorated (on headache-
specific transition question) at 12-weeks.16 An area under the curve (AUC) score of > 0.70 is 
considered sufficiently discriminatory; an AUC of 0.5 suggests no discriminatory power.  
iii.  Effect size (ES) and Standardized Response Mean (SRM) 
The effect size and standardised response mean were calculated for subgroups of patients in 
each health transition category. The main hypotheses we tested were: ES and SRM would be 
<0.2 for patients who reported no change in headache; >0.2 for patients reporting a slight 
improvement; >0.5 for patients reporting improvement (much better); greater for patients 
indicating an improvement in their headache than those indicating no change. 
 
Content validity  
Semi-structured cognitive interviews were conducted within 24-hours of questionnaire self-
completion with a purposive sample (age, gender, headache type) of participants. 
Measurement relevance, acceptability, clarity and comprehensiveness was explored.21, 22 
Overarching questions explored how patients determined headache improvement, and if 
specific questions were missing. Interviews continued until thematic saturation was achieved; 
were audio-recorded, transcribed verbatim, and checked for accuracy (VN). We used 
Framework analysis23 and cross-case comparison to generate themes. NVivo software (QSR 





explored by two researchers (VN, KH); emergent themes were discussed and interpreted with a 








We recruited 131 people: 130, 115 (88%) and 103 (79%) questionnaires were completed at 
baseline, two and 12-weeks, respectively (Table 1).11  
 
Data quality and interpretability 
Item missing data for the CHQLQ was low (range 0% to 3%); domain scores were computable 
for 96% (role-prevention), 97% (role-restriction) and 100% (emotional function) of respondents 
(Table 2). All response options were endorsed. Except item 12 ('fed up or frustrated'), which 
correlated more highly with role-restriction (0.71) than emotional function domain (0.64), all 
item-total correlations with specified domains were greater than 0.7 (Table 3).  
There were no missing data for the HIT-6; index scores were computable for all responders. 
Except for item 1 (pain severity), for which response option 1 ('never') was not endorsed, all 
response options were supported. Item-total correlations ranged from 0.68 to 0.79, with five of 
the six items achieving scores higher than 0.70 (Table 3).  
Floor-effects (>15%) were identified for three CHQLQ role-prevention items and two emotional 
function items, suggesting many respondents were not 'prevented' from undertaking usual 
activities or experienced specific emotional difficulties (Table 2). Ceiling-effects were observed 
for two HIT-6 items: > 15% respondents indicated they would 'always' 'lie down' or feel 'fed up 
or irritated' when experiencing a headache, suggesting the importance of these items, but 






Structural validity and internal consistency 
Standard loadings and goodness-of-fit indices for the CHQLQ exploratory factor analysis 
supported the three-factor model, with factor loadings >0.50 for all items except item 12 ('fed 
up or frustrated') (Table 3). Role-restriction accounted for the majority (43%) of data total 
variance. Confirmatory factor analysis produced a good data fit, supporting the CHQLQ’s three-
domain model. Confirmatory factor analysis supported the HIT-6 single domain, with all 
component loadings > 0.70. Cronbach's alpha ranged 0.87 to 0.94 for the CHQLQ domains and 
0.90 for the HIT-6, indicating high internal consistency.  
 
Reliability 
All values for the CHQLQ and HIT-6 exceeded the lower threshold for acceptable test-retest 
reliability (intra-class correlation coefficient > 0.70), supporting use with groups of patients 
(Table 4). The standard error of measurement for the CHQLQ domains were 8.09 (role-
restriction), 8.46 (role-prevention) and 10.58 (emotional function), resulting in smallest 
detectable change for individuals (SDCindividual) values of 22.42, 23.45 and 29.32, respectively. 
The corresponding smallest change in scores that can be detected at the group level (SDCgroup) 
was 2.74 (role restriction), 2.86 (role prevention) and 3.58 (emotional function). This implies 
that, when using the CHQLQ for individual assessment, changes in people with stable symptoms 
would need to be greater than 22, 24 or 29 points (between 22% and 29% of total score 





means would need to differ between 2.74 and 3.58 (up to 4% of total score change) to ensure a 
true detection of a difference in people with stable symptoms.  
The standard error of measurement for the HIT-6 was 2.42, resulting in a SDCindiviudal of 6.69 and 
SDCgroup of 0.78. When using the HIT-6 in individual assessment, changes in people with stable 
symptoms would need to exceed 6.7 points (16% of total score change) to be distinguishable 
from measurement error. Alternatively, on a group level, group means need to differ by 0.78 
(up to 2% of total score change) to be distinguishable from measurement error in people with 
stable symptoms.  
 
Construct validity 
Most hypothesised associations were supported (Table 5): the CHQLQ’s three domains were 
strongly associated, with moderate to strong associations with the HIT-6. However, the 
association between role-restriction and the SF-12 mental component score was stronger 
(moderate) than that observed with emotional function, reflecting the emotional component of 
the role-restriction domain. Similarly, although smaller than hypothesised, associations 
between role-restriction and the HADS were similar or greater than that observed for 
emotional function, reflecting the limited emotional content of the emotional function domain 
specifically, and the CHQLQ generally. Moderate associations between the CHQLQ and Social 
Impact Scale and Pain Self-Efficacy Scales reflect the CHQLQ focus on the social impact of 






A strong association with the Pain Self-Efficacy Questionnaire reflects the HIT-6 focus on pain. 
Apart from the moderate association with the Social Impact Scale, reflecting the HIT-6 emphasis 
on social impact, small associations with the remaining measures evidence a limited focus on 
the emotional impact of headache. 
 
Responsiveness (Table 6) 
Of the 105 people completing the 12-week questionnaire, 94 and 100 completed the health-
transition question and CHQLQ or HIT-6, respectively. 
Smallest Detectable Change (SDC) 
The CHQLQ standard error of measurement ranged from 5.60 to 10.31 for participants 
indicating minimal improvement or deterioration in headache status at 12-weeks. The resultant 
smallest detectable change for individuals (SDCindividual) for improvement ranged between 15 
(role-prevention) to 21 (role-restriction), and 26 (role-restriction and role-prevention) to 28 
(emotional function) for deterioration. The corresponding smallest detectable change for 
groups (SDCgroup) ranged between 3 (role-prevention) to 5 (role-restriction) for improvement, 
and 7 (role-prevention) to 8 (emotional function) for deterioration. These results imply that 
when using the CHQLQ for individual assessment, changes of <21 (improvement) or <28 
(deterioration) points cannot be distinguished from error. However, much smaller differences 
are detectable for groups of patients: for groups who indicate minimally improvement, a 
change from baseline to 12-weeks of >5 points on the role-restriction and emotional function 
domains and >4 on the role-prevention domain are required to demonstrate a change that is 





approximately 8 points is required to demonstrate change that is greater than measurement 
error.  
The standard error of measurement for the HIT-6 ranged 1.7 (deterioration) to 3.5 
(improvement). The smallest detectable change at the individual level (SDCindividual ) was 9.5 and 
1.7, and at the group level (SDCgroup) was 2.1 and 1.3 for improvement and deterioration, 
respectively. 
 
Minimal important change (MIC) 
Fifty-three of the 94 valid CHQLQ responses at 12-weeks (56%) indicated no change in 
headache status (mean change in score between 2.57 (SD 13.6)(emotional function) and 7.04 
(SD 13.35)(role-restriction)). Nineteen reported some ('better') improvement, with a mean 
score improvement (minimally important change) of 5.26 (role-prevention), 8.00 (emotional 
function) and 10.79 (role-restriction). The remaining 12 participants reported a deterioration 
('worse') in headache status and a mean score deterioration of -0.75 (role-prevention), -2.25 
(emotional function), and -3.17 (role-restriction). The smallest difference between clinically 
stable and improved participants (i.e., the minimal clinically important difference (MCID)) was 
0.84 (role-prevention), 3.75 (role-restriction) and 5.43 (emotional function).  
The minimally important change for the HIT-6 is -3.15 and 0.42 for minimal improvement and 
deterioration, respectively. The smallest difference between clinically stable and improved 





For both measures, the minimal important changes were greater than the smallest detectable 
change in groups (SDCgroup), indicating that a greater change in score is required to denote 
'important change' than that required to illustrate change that is greater than measurement 
error.  
Criterion-based responsiveness (Figure 1) 
Moderate correlations between CHQLQ and HIT-6 change scores with the headache-specific 
transition item (range -0.35 (emotional function) to -0.45 (role-prevention); 0.36 (HIT-6)), 
supported its use as an external marker of change.24 The higher AUC scores were found when 
dichotomising patients according to those who were 'Much better' versus those reporting that 
they were 'better, the same or worse' (Figure 1). Two (role-restriction, emotional function) 
CHQLQ domains exceeded 0.70 (lower bound 95% CI exceeding 0.50), indicating adequate 
responsiveness. However, the AUC for the role-prevention domain was 0.68, with a lower 
bound 95% CI of 0.53 (95% CI 0.53-0.84), suggesting limited responsiveness. The AUC for the 
HIT-6 exceeded 0.70 (95% CI 0.64 – 0.92). At this level of discrimination, these results suggest 
adequate responsiveness. However, AUC less than 0.70 were found when participants were 
grouped differently (Figure 1).  
 
Effect size statistics  
As hypothesised, both effect size and standardised response means for patient subgroups 
increased with increased reported improvement on the transition question. Moderate to large 
effect sizes were found for people reporting some (better) and greater (much better) 





patients being unchanged, most values (75%) did not confirm the hypothesis by exceeding 0.2. 
Small numbers limited interpretation of any headache deterioration. 
 
Content validity  
We interviewed 14 participants (age 21-72 years; nine female) with chronic migraine. 
Typically, participants felt the CHQLQ was relevant to their headache experience, specifically 
welcoming the emotional impact items. However, item overlap - particularly around work - 
caused participants to refer back to previous items, and increased completion time. Participants 
described experiencing different headache intensities across the four-week recall period, 
requiring judgement as to how they selected the most appropriate response. Double-barrelled 
items that aligned headache impact on 'work' with 'leisure activities' or 'home' were 
challenging as different environments influenced response. Contextual situations—for example, 
being retired or without dependents – caused participants to rate headache impact differently.  
Typically, participants felt that the HIT-6 was relevant, welcoming its brevity and simplicity. 
However, when considering different headache intensities, the lack of recall-period (items 1 to 
3) was problematic: a range of recall periods (daily, weekly, fortnightly, monthly, study 
duration) were reported to assist in completion. The lack of ‘pain severity’ definition (item 1) 
was problematic - participants made their own judgement of severity before answering. The 
double-barrelled nature of three items (2,5,6) caused concern. The impact of headache on 
work, social or household activities could be scored differently - some chose one activity, 





'wishing' that one could lie down versus ‘actually’ being able to lie down; item 4 – what was 










This comparative evaluation of the CHQLQ (adapted MSQ v2.1) and HIT-6 found the 
appropriateness of the CHQLQ as a measure of headache-specific quality of life was supported. 
Whilst the HIT-6 was similarly strong, concerns over content and relevance were identified.  
Although the shortness of the HIT-6 was welcomed, the capture of headache impact was 
limited when compared to the CHQLQ. The CHQLQ questions addressing the emotional, 
symptomatic and social impact of headache were appreciated. However, item repetition and 
redundancy unnecessarily increased completion time. Participants 'averaged' responses to 
manage the CHQLQ’s four-week recall period; however, the lack of recall period for several HIT-
6 items was a greater concern. This limitation was not identified by the quantitative analysis, 
highlighting the importance of seeking end-user perspectives throughout development and 
testing. Low levels of missing data supported the acceptability of both measures. 
The CHQLQ three-factor model was supported. However, the dual loading of item 12 (‘fed-up or 
frustrated’) on both role-restriction and emotional function domains suggested multiplicity and 
interpretation problems,25 which was further supported by a stronger item-total correlation 
with the role-restriction domain than with the emotional function domain. Qualitative 
interviews further identified CHQLQ item interplay between domains, describing the 
importance of context when thinking about headache impact. Similar contextual problems, 
including a noticeable divide between work and social commitments was described for both the 
CHQLQ and HIT-6: for example, interviewee's reported endeavouring to keep going whilst at 





The magnitude of the between-domain correlations found in our work suggest that the CHQLQ 
domains are measuring somewhat different aspects of headache-related health and should be 
retained. Our confirmatory factor analysis and work by Rendas-Baum et al. (2013)26 further 
support this. High alpha values supported the internal consistency of the three CHQLQ 
domains. Similarly, high alpha values have been reported for the MSQv2.1 following completion 
by patients with chronic27, 28 and episodic migraine.8, 27  
The single-domain structure of the HIT-6 was supported by both factor analysis and high alpha 
values, confirming evidence following completion across chronic and episodic headache 
populations.29, 30  
Low reliability was reported for the MSQv2.1 (ICC < 0.70) in patients with ‘stable’ episodic 
migraine at a 4-week re-test.26 Acceptable levels have been reported for the HIT-6.29, 30 The high 
levels of reliability in this study support application of both measures in groups, with the 
smallest detectable change (SDC) suggesting a CHQLQ difference in group means greater than 
2.74 (role-restriction), 2.86 (role-prevention) and 3.58 (emotional function) and 0.78 for the 
HIT-6 is required to demonstrate a real change in stable patients.  
Associations between different variables provided acceptable evidence of CHQLQ and HIT-6 
construct validity, consistent with earlier MSQv2.126, 28 and HIT-69, 31 evaluations. However, the 
CHQLQ’s emotional function domain association with alternative measures of emotional 
wellbeing were less than hypothesised. Given the importance afforded by patients to the 
emotional impact of headache, the inclusion of measures providing a more nuanced 






Both measures demonstrated acceptable evidence of responsiveness to headache 
improvement over 12-weeks. Moreover, two CHQLQ domains (role-restriction, emotional 
function) and the HIT-6 discriminated between dichotomous configurations of self-reported 
change in health when grouped as 'much better' versus 'better, same or worse'. The role-
prevention domain was unable to discriminate at a higher level of discrimination.  
The minimal important change (MIC) values for both measures were greater than the smallest 
detectable change (SDC) for groups of patients whose headaches had minimally improved, 
indicating an 'important change' for participants is greater than measurement error. The 
minimally important change values for CHQLQ domains closely approximate those reported 
following a 3-month completion of the MSQv2.1 by a large US, mixed population of migraineurs 
- role-restriction 5, role-prevention 5 to 7.9, emotional function 8.0 to 10.6.32 
The HIT-6 minimal important change value closely approximates that determined in US patients 
with chronic headache (-3.7)33 and Dutch patients with episodic migraine (-2.5).34 However, it is 
smaller than a minimal important change of 8.0 proposed in a Dutch study of patients with 
tension-type headache,35 where global improvement was defined according to both global 
improvement and a reduction in headache days (greater than 50%);. Published minimal 
important change values for the HIT-6 range from -1.5 (episodic migraine) to -2.3 (chronic daily 
headache),7, 33-35 approximating the minimal clinical important difference (MCID) of -1.06 found 





This study describes the first, mixed methods comparative evaluation of two generic, headache-
related quality of life measures that are not diagnosis specific, in a UK-based cohort of patients 
living with chronic headaches. Despite the importance of content validity to the relevance and 
acceptability of measures, few PROM evaluative studies explore the qualitative aspects of 
measures.7 Whilst both measures demonstrated comparable psychometric properties, 
qualitatively, the content validity of the CHQLQ was enhanced by the inclusion of items 
assessing the emotional toil of chronic headache. However, all interviews were conducted with 
people with definite or probable chronic migraine, potentially limiting the generalisability of 
these findings to other headache types. Whilst the number of participants were adequate to 
support a robust evaluation of measurement data quality, reliability and validity, the majority of 
participants reported ‘no change’ in health at the 12-week follow-up, substantially reducing the 
numbers available to explore measurement responsiveness. Further evaluations of 
measurement responsiveness in a larger cohort and following an active intervention will further 
enhance confidence in the measures ability to capture important change, and towards 
calculation of the minimal important change in score. Evidence suggests that the CHQLQ shows 
potential for further use in other groups of patients with chronic headache, but this analysis is 
limited to participants in a feasibility study (for a larger trial).12 Hence, some caution is required 
in generalizing conclusions and recommendations more widely to the general population of 
people with chronic headaches. 
Since the reported PROM evaluation was explicitly in people without a specific headache 
diagnosis, the evidence supports application of both measures in trials where recruitment takes 





epidemiologic surveys - for example, capturing the impact of headache disorders.  Further work 
may be needed to evaluate use of the CHQLQ in other populations of people with chronic 
headaches where case mix may be different.  For example, it might be a useful measure for 
people with definite chronic migraine and medication overuse headache after further 
evaluation in that population. That the design of this study did not allow a precise diagnosis on 
all participants is not a weakness since the evaluation sought to provide evidence in support of 
the CHQLQ when assessing people with undiagnosed headache disorder. 
Conclusion 
This study describes the first comparative evaluation of the new CHQLQ with the HIT-6, 
demonstrating the added value to be gained from a mixed-methods approach to PROM 
evaluation. The results of this study, and the consistency with previous evaluations, supports 
recommendation of the CHQLQ as a high quality, relevant and acceptable measure for chronic 
headache. In comparison to the HIT-6, for which similarly strong psychometric evidence was 







 The quality, relevance and acceptability of a new measure of chronic headache quality 
of life – the Chronic Headache Quality of Life Questionnaire (CHQLQ) was compared 
with that of an existing measure – the 6-item Headache Impact Text (HIT-6) following 
completion in a UK population. 
 The CHQLQ better captured the emotional, symptomatic and social impact of chronic 
headache. 
 Both measures has comparable measurement properties. 
 The CHQLQ is recommended as a high quality, relevant and acceptable measure for use 
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